Related Experiment Video
Updated: Aug 23, 2025

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
Published on: November 2, 2018
IRAK1 Duplication in MECP2 Duplication Syndrome Does Not Increase Canonical NF-κB-Induced Inflammation
Ilona Gottschalk1,2, Uwe Kölsch3, Dimitrios L Wagner2,4,5,6
1Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
Purpose:
Besides their developmental and neurological phenotype, most patients with MECP2/IRAK1 duplication syndrome present with recurrent and severe infections, accompanied by strong inflammation. Respiratory infections are the most common cause of death. Standardized pneumological diagnostics, targeted anti-infectious treatment, and knowledge of the underlying pathomechanism that triggers strong inflammation are unmet clinical needs. We investigated the influence of IRAK1 overexpression on the canonical NF-κB signaling as a possible cause for excessive inflammation in these patients.
Methods:
NF-κB signaling was examined by measuring the production of proinflammatory cytokines and evaluating the IRAK1 phosphorylation and degradation as well as the IκBα degradation upon stimulation with IL-1β and TLR agonists in SV40-immortalized fibroblasts, PBMCs, and whole blood of 9 patients with MECP2/IRAK1 duplication syndrome, respectively.
Results:
Both, MECP2/IRAK1-duplicated patients and healthy controls, showed similar production of IL-6 and IL-8 upon activation with IL-1β and TLR2/6 agonists in immortalized fibroblasts. In PBMCs and whole blood, both patients and controls had a similar response of cytokine production after stimulation with IL-1β and TLR4/2/6 agonists. Patients and controls had equivalent patterns of IRAK1 phosphorylation and degradation as well as IκBα degradation upon stimulation with IL-1β.
Conclusion:
Patients with MECP2/IRAK1 duplication syndrome do not show increased canonical NF-κB signaling in immortalized fibroblasts, PBMCs, and whole blood. Therefore, we assume that these patients do not benefit from a therapeutic suppression of this pathway.
Insights
Patients with MECP2/IRAK1 duplication syndrome do not exhibit heightened NF-κB signaling, suggesting that suppressing this pathway may not benefit them. This finding impacts potential treatments for severe infections and inflammation in these patients.
Area of Science:
- Immunology
- Genetics
- Molecular Biology
Background:
- MECP2/IRAK1 duplication syndrome is characterized by developmental issues, neurological deficits, and severe, recurrent infections often leading to fatal respiratory complications.
- The underlying cause of excessive inflammation in these patients remains unclear, representing a significant unmet clinical need.
- Investigating the role of IRAK1 overexpression in inflammatory pathways is crucial for understanding disease pathogenesis.
Purpose of the Study:
- To investigate the influence of IRAK1 overexpression on canonical NF-κB signaling as a potential driver of excessive inflammation in MECP2/IRAK1 duplication syndrome.
- To determine if increased NF-κB signaling is present in patients with this syndrome.
- To inform potential therapeutic strategies targeting inflammatory pathways.
Main Methods:
- Assessed NF-κB signaling by measuring proinflammatory cytokine production (IL-6, IL-8).
- Evaluated IRAK1 and IκBα degradation patterns following stimulation with IL-1β and TLR agonists.
- Utilized SV40-immortalized fibroblasts, peripheral blood mononuclear cells (PBMCs), and whole blood from 9 patients and healthy controls.
Main Results:
- No significant difference in IL-6 and IL-8 production was observed between patients and controls in response to IL-1β and TLR agonists in fibroblasts, PBMCs, and whole blood.
- IRAK1 phosphorylation and degradation, as well as IκBα degradation, showed equivalent patterns in both patients and controls upon IL-1β stimulation.
- Canonical NF-κB signaling activation was not elevated in MECP2/IRAK1-duplicated patients across all tested cell types.
Conclusions:
- Patients with MECP2/IRAK1 duplication syndrome do not exhibit increased canonical NF-κB signaling.
- Therapeutic suppression of the canonical NF-κB pathway is unlikely to benefit these patients.
- Further research is needed to identify the mechanisms driving inflammation in MECP2/IRAK1 duplication syndrome.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Regulation of the Unfolded Protein Response
MAPK Signaling Cascades
Master Transcription Regulators
Co-activators and Co-repressors
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

